Breast Cancer Research and Treatment

, Volume 3, Issue 1, pp 85–89 | Cite as

Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: A phase I–II study

  • H. T. Mouridsen
  • E. Boesen
Scandinavian Breast Cancer Symposium


Forty-seven patients with advanced breast cancer were treated with a combination of prednimustine (P), methotrexate (M), 5-fluorouracil (F), and tamoxifen (TAM). Twenty-six patients received P, 80 mg/m2 day 1–5 (series I) and 21 patients received P, 100 mg/m2 day 1–5 (series II). Both series of patients received M, 40 mg/m2 day 1 and 8 and F, 600 mg/m2 day 1 and 8 with a cycle duration of 4 weeks. All patients received TAM 20 mg twice daily. As concerns the haematologic toxicity, WBC were depressed significantly more often than platelet counts, and during the first 3 cycles 70% of the patients had a WBC nadir corresponding to toxicity grade II or more. No signs of cumulative haematologic toxicity were observed. Nausea and vomiting were registered in 40 out of 47 patients but in 35 of these only of grade I–II. Only one patient developed alopecia requiring a wig. The response to treatment could be evaluated in 28 patients, 21 of whom experienced response (CR or PR) of a median duration of 13 months.

In conclusion, it seems that prednimustine can be safely used in combination with methotrexate and 5-fluorouracil. The frequency of alopecia is definitely lower than with CMF. Whether this relates also to subjective side effects will require a randomized study, as will a final conclusion concerning the efficacy compared to that of CMF.


breast cancer clinical trials prednimustine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Harrap KR, Riches PG, Gilby ED, Sellwood SM, Wilkinson R, Könyves I: Studies on the toxicity and antitumor activity of prednimustine, a prednisolone ester of chlorambucil. Eur J Cancer 13:873–881, 1977PubMedGoogle Scholar
  2. 2.
    Evenaar AH, Wins EHR, Van Putten LM: Cell killing effectiveness of an alkylating steroid (Leo 1031). Eur J Cancer 9:773–774, 1973PubMedGoogle Scholar
  3. 3.
    Fredholm B, Gunnarsson K, Jensen G, Müntzing J: Mammary tumor inhibition and subacute toxicity in rats of prednimustine and its molecular components chlorambucil and prednisolone. Acta Pharmacol et Toxicol 42:159–163, 1978Google Scholar
  4. 4.
    Könyves I, Nordenskjöld B, Plym-Forshell G, De Schryver A, Westerberg-Larsson H: Preliminary clinical and absorption studies with prednimustine in patients with mammary carcinoma. Eur J Cancer 11:841–844, 1975PubMedGoogle Scholar
  5. 5.
    Mouridsen HT, Kristensen D, Halskov-Nielsen J, Dombernowsky P: Phase II trial of prednimustine, L-1031 (NSC-134087) in advanced breast cancer. Cancer 46:253–255, 1980PubMedGoogle Scholar
  6. 6.
    Johansson JE, Tropé C, Mattsson W, Grundsell H, Aspegren K, Könyves I: Phase II study Leo 1031 (prednimustine) in advanced ovarian carcinoma. Cancer Treat Rep 63:421, 1979PubMedGoogle Scholar
  7. 7.
    Lele SB, Piver MS, Barlow J, Murphy GP: Leo 1031 (NSC-134087) in gynecologic malignancies. Oncology 35:101, 1978PubMedGoogle Scholar
  8. 8.
    Catane R, Kaufman JH, Madajewicz S, Mittelman A, Murphy GP: Prednimustine therapy for advanced prostatic cancer. Brit J Urol 50:29, 1978PubMedGoogle Scholar
  9. 9.
    Clinical Screening Cooperative Group of EORTC: A phase II clinical trial of prednimustine. Biomed 27:158–161, 1977Google Scholar
  10. 10.
    Løber J, Mouridsen HT, Christiansen IE, Dombernowsky P, Mattsson W, RØrth M: A phase III trial comparing prednimustine (Leo 1031) to chlorambucil plus prednisolone in advanced breast cancer. Cancer: in pressGoogle Scholar
  11. 11.
    Carter SK: Integration of chemotherapy into combined treatment of solid tumors. VII. Adeno-carcinoma of the breast. Cancer Treat Rev 3:141–174, 1976PubMedGoogle Scholar
  12. 12.
    Rozencweig M, Heuson JC, von Hoff DD, Mattheiem WH, Davis HL, Muggia FM: Breast cancer.In MJ Staquet (ed). Randomized Trials in Cancer. A Critical Review by Sites. Raven Press, New York, 1978 pp 231–272Google Scholar
  13. 13.
    Mouridsen HT, Palshof T, Engelsman E, Sylvester R: CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial. Eur J Cancer Suppl:119–123, 1980Google Scholar
  14. 14.
    Cocconi G, Leasi BD, Boni C, Mori P: Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study. UICC Conf Clin Oncol Breast Cancer Abstr: 03–0141, 1981Google Scholar
  15. 15.
    WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48, Geneva, 1979Google Scholar
  16. 16.
    Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Cancer 39:1289–1294, 1977PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers 1983

Authors and Affiliations

  • H. T. Mouridsen
    • 1
  • E. Boesen
    • 1
  1. 1.Department of Oncology AThe Finsen InstituteCopenhagenDenmark

Personalised recommendations